Congress Materials – Pulmonary Hypertension Professional Network Symposium (PHPN)
2025 PH Professional Network Symposium | Sep 18-20 | Seattle, WA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
A real-world retrospective study evaluating a Team-based patient Engagement Approach to selexipag initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH)
Amanda Schnell Heringer, Samuel B Brusca, Sarah E Walden, Gurinderpal S Doad, Christina K Benninger, Paul M Strachan, Mark J Lacsamana, Anya Thakur, Jonathan G Thomas, Sara Bravo, Ambika Satija, Gayatri J Marathe, Henrietta Blinder, Marjolaine Gauthier-Loiselle, Teresa De Marco
Characteristics and treatment patterns of patients initiated on or transitioned to OPSYNVI® (macitentan/tadalafil single tablet combination therapy) for treatment of pulmonary arterial hypertension
Mrinalini Krishnan, Nicholas A Kolaitis, Marinella Sandros, Ankita Adhia, David Lopez, Natalie Gearhart, Alexander K Salomon, John J. Ryan
Delphi study to elicit consensus on best practice for prior authorization in pulmonary arterial hypertension
Zeiger T, Alvadzhyan V, Marcello K, Carollo B, Perry R, Stone MA, Nuttall LA, Sandros M, Dong J, Lopez D, Gomez Rendon G, Adhia A, Benninger C, Muralidhar A
Oral selexipag in methamphetamine-associated pulmonary arterial hypertension: Real-world analysis from TEAM PAH
Amanda Schnell Heringer, Samuel B Brusca, Sarah E Walden, Gurinderpal S Doad, Christina K Benninger, Paul M Strachan, Mark J Lacsamana, Anya Thakur, Jonathan G Thomas, Sara Bravo, Ambika Satija, Gayatri J Marathe, Henrietta Blinder, Marjolaine Gauthier-Loiselle, Teresa De Marco
Pre-planned study design adaptations in UNISUS: a Phase 3, randomized superiority study comparing the efficacy, safety and tolerability of macitentan 75 mg versus 10 mg in patients with pulmonary arterial hypertension (PAH)
Vallerie McLaughlin, Yuichi Tamura, Marc Humbert, Arthur Backer, Neli Boyanova, Hilke Kracker, Anna Larbalestier, Lilian Sanna, Gurinderpal Doad, Marius Hoeper
Real-world adherence and persistence of upfront therapy in patients with pulmonary arterial hypertension in the United States
Teresa De Marco, Carly J Paoli, Nicole S Croteau, Fei Tang, Harrison W Farber
Structured expert elicitation to generate estimates for the administrative workload associated with prior authorization in pulmonary arterial hypertension (PAH)
Akshay Muralidhar, Valentina Alvadzhyan, Brett Carollo, Tonya Zeiger, Marinella Sandros, Ankita Adhia, Gabriela Gomez Rendon, David Lopez, Korawin Triyasakorn, Gregory Smith, Danielle Riley, Aimee Fox, Olivia Dodd, Jeremy Ord, Kelly Marcello
Transitioning prostacyclin pathway agents to oral selexipag in patients with pulmonary arterial hypertension: A systematic literature review
Jean Elwing, Krishnan, Kishan Parikh, Therese Sargent, Sheryl Wu, Christina BMrinalinienninger, Gurinderpal Doad, Wendy Hill, Charlotte Oswald, Daisy Bridge, Peter O’Donovan, Luis Val-Maranes, Chad Miller
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
